Acquisition context Gecko Health Innovations was acquired by Teva Pharmaceuticals in 2015, indicating established industry interest and potential integration with a larger health-care portfolio.

Asthma focus Primary target is pediatric asthma management through the CareTRx device, offering opportunities to expand within families and connect with pediatric clinics, schools, and allergy/immunology practices.

Market potential Asthma remains a leading cause of pediatric hospitalization with substantial patient population and admissions, suggesting room to scale adherence tools across regional health systems and Medicaid/CHIP programs.

Sales angles Partnership opportunities with large device-using inhaler manufacturers or distributors, leveraging Teva's network to expand adoption of monitoring and reminder solutions in both hospital and outpatient settings.

Tech and trust Low employee count and a web-centric tech stack imply agility but also a need for scalable implementation support, training for clinicians, and robust customer success to drive evidence-based adoption.